In England, the National Health Service (or NHS) is exploring an ambitious plan: testing newborns’ DNA to check for disease risks. Using genomics and AI, the goal is to speed up diagnoses and catch illnesses early. Sounds good, right? Spot issues early, save lives — it’s a no-brainer. But hold on, it’s not quite that simple.
A recent NHS pilot project has already sequenced the genomes of 100,000 babies to check for more than 200 conditions. However, these tests don’t give clear-cut answers — they only provide a risk estimate. And here’s the tricky part: risk isn’t the same as a diagnosis. Terms like “high risk” or “likely” might sound straightforward, but they can cause confusion. Studies show while some people grasp what risk scores mean, many interpret “high risk” more seriously than they should — and even doctors sometimes overestimate what these results actually indicate.
This is where things get messy. In genomics, the line between “you might get sick” and “you will get sick” gets blurry fast. Policymakers don’t help either, throwing around phrases like “diagnosis before symptoms” or “leapfrogging disease.” These sound exciting, but they can lead to over-testing, unnecessary treatments, or even psychological harm. Imagine growing up thinking you’ll get sick one day, only to realize you never do. That’s not just stressful — it can shape your identity and decisions in ways that stick with you.
But that’s not all — there are more concerns about how genetic testing might affect people’s lives in time.
When applied to the general population, where most people are healthy, broad DNA screening can create more problems than it solves. Research shows even well-designed tests can produce more false positives than true results, as seen during the COVID pandemic. False positives cause unnecessary stress, extra testing, and even harmful treatments. For example, Alzheimer’s tests in healthy populations are wrong up to two-thirds of the time, according to research published in European Neurology.
And it doesn’t stop there. In 2022, a New York Times investigation found noninvasive prenatal tests (or NIPT) for rare conditions are wrong a shocking 80% to 93% of the time. Even worse, the US Food and Drug Administration doesn’t regulate the accuracy or marketing of these tests, and labs don’t have to share performance data. This lack of oversight opens the door to serious harm for patients.
Of course, there’s big money in all of this. According to Grand View Research, the global genomics market is worth more than $32 billion, so this isn’t just about improving health — it’s about business. The NHS Digital shows Genomics England already shares patient data with businesses. Add AI to the mix, and concerns about surveillance grow even bigger, with potential for digital IDs that combine biometric and genomic data. Sure, the health benefits could be huge, but ethical issues like consent and transparency can’t be brushed aside.
So, while DNA testing for newborns might sound like a step into the future, it comes with a lot of questions we need to answer first. The stakes are high, and it’s about more than just science — it’s about trust, ethics, and the balance between innovation and responsibility.
